


## Antitumor agent-114

Cat. No.:	HY-155109
CAS No.:	2757762-91-5
Molecular Formula:	C <sub>39</sub> H <sub>50</sub> F <sub>2</sub> N <sub>10</sub> O <sub>13</sub> P <sub>2</sub>
Molecular Weight:	966.82
Target:	STING
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Antitumor agent-114 is a potent stimulator of interferon genes (STING) agonist. Antitumor agent-114 activates immunity and reduces tumor volume in a mouse model of breast cancer. Antitumor agent-114 can be used for immunity and cancer diseases research <sup>[1]</sup> .								
<b>In Vivo</b>	<p>Antitumor agent-114 (compound 14c) (2, 0.67, 0.22 mg/kg for intratumoral on day 1, 4, and 7) modulates tumor eradication by systemic immune activation in 4T1 tumor-bearing mice model<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>4T1 tumor-bearing mice model<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>2, 0.67, 0.22 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intratumoral (i.t.)</td> </tr> <tr> <td>Result:</td> <td>Reached 80 and 70% tumor growth inhibition (TGI) in the groups treated with 2 and 0.67 mg/kg. Induced tumor regression in 7 of 8 mice at a dose of 2 mg/kg.</td> </tr> </table>	Animal Model:	4T1 tumor-bearing mice model <sup>[1]</sup>	Dosage:	2, 0.67, 0.22 mg/kg	Administration:	Intratumoral (i.t.)	Result:	Reached 80 and 70% tumor growth inhibition (TGI) in the groups treated with 2 and 0.67 mg/kg. Induced tumor regression in 7 of 8 mice at a dose of 2 mg/kg.
Animal Model:	4T1 tumor-bearing mice model <sup>[1]</sup>								
Dosage:	2, 0.67, 0.22 mg/kg								
Administration:	Intratumoral (i.t.)								
Result:	Reached 80 and 70% tumor growth inhibition (TGI) in the groups treated with 2 and 0.67 mg/kg. Induced tumor regression in 7 of 8 mice at a dose of 2 mg/kg.								

### REFERENCES

[1]. Dejmek M, et al. Vinylphosphonate-based cyclic dinucleotides enhance STING-mediated cancer immunotherapy. *Eur J Med Chem.* 2023 Nov 5;259:115685.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA